Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Cartin-Ceba, K. Swanson, M. Krowka (Rochester, United States Of America). Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy. Eur Respir J 2012; 40: Suppl. 56, 949

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of tadalafil in portopulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension Source: Eur Respir J 2013; 41: 96-103 Year: 2013 Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Efficacy and safety of bosentan in portopulmonary hypertension according to the severity of liver disease Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Long-term safety and efficacy of imatinib in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Iloprost treatment in portopulmonary hypertension Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008 Combination therapy with sildenafil and sitaxentan therapy for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Experience with inhaled iloprost and bosentan in portopulmonary hypertension Source: Eur Respir J 2007; 30: 1096-1102 Year: 2007 Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007 Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension Source: Eur Respir J, 53 (1) 1801880; 10.1183/13993003.01880-2018 Year: 2019 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: 563-567 Year: 2006 Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005 Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Efficacy and safety of oral bosentan in patients with Down‘s syndrome and pulmonary arterial hypertension due to congenital heart disease Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH Year: 2012 Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005